248 related articles for article (PubMed ID: 12491771)
1. [Anti-dementia drugs for Alzheimer disease in present and future].
Nabeshima T; Noda Y; Kamei H
Nihon Yakurigaku Zasshi; 2002 Nov; 120(1):24P-29P. PubMed ID: 12491771
[TBL] [Abstract][Full Text] [Related]
2. [Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Shimohama S
Rinsho Shinkeigaku; 2013; 53(11):1036-8. PubMed ID: 24291871
[TBL] [Abstract][Full Text] [Related]
3. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Jann MW; Shirley KL; Small GW
Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
[TBL] [Abstract][Full Text] [Related]
5. Acetylcholinesterase inhibition in Alzheimer's Disease.
Ibach B; Haen E
Curr Pharm Des; 2004; 10(3):231-51. PubMed ID: 14754384
[TBL] [Abstract][Full Text] [Related]
6. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Musiał A; Bajda M; Malawska B
Curr Med Chem; 2007; 14(25):2654-79. PubMed ID: 17979717
[TBL] [Abstract][Full Text] [Related]
7. Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Hake AM
Cleve Clin J Med; 2001 Jul; 68(7):608-9, 613-4, 616. PubMed ID: 11453078
[TBL] [Abstract][Full Text] [Related]
8. [Neurobiology and modern approaches to the treatment of Alzheimer disease].
Levada OA
Lik Sprava; 2003; (7):12-6. PubMed ID: 14723127
[TBL] [Abstract][Full Text] [Related]
9. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of Alzheimer's disease: status quo and future considerations].
Shimohama S
Nihon Yakurigaku Zasshi; 2008 May; 131(5):351-6. PubMed ID: 18480565
[No Abstract] [Full Text] [Related]
11. Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Van Dam D; Abramowski D; Staufenbiel M; De Deyn PP
Psychopharmacology (Berl); 2005 Jun; 180(1):177-90. PubMed ID: 15654502
[TBL] [Abstract][Full Text] [Related]
12. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
Ritchie CW; Ames D; Clayton T; Lai R
Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
[TBL] [Abstract][Full Text] [Related]
13. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
14. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibitors for Alzheimer's disease.
Grutzendler J; Morris JC
Drugs; 2001; 61(1):41-52. PubMed ID: 11217870
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
17. [New anti-AD drugs--their possibilities and issues].
Nakamura Y
Seishin Shinkeigaku Zasshi; 2012; 114(3):255-61. PubMed ID: 22568059
[TBL] [Abstract][Full Text] [Related]
18. Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors.
Arias E; Gallego-Sandín S; Villarroya M; García AG; López MG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1346-53. PubMed ID: 16144975
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Kabir MT; Uddin MS; Begum MM; Thangapandiyan S; Rahman MS; Aleya L; Mathew B; Ahmed M; Barreto GE; Ashraf GM
Curr Pharm Des; 2019; 25(33):3519-3535. PubMed ID: 31593530
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibitors stabilize Alzheimer's disease.
Giacobini E
Ann N Y Acad Sci; 2000; 920():321-7. PubMed ID: 11193171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
